Amarantus BioScience Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMBS research report →
About the company
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine.
- CEO
- John Wesley Commissiong
- IPO
- 2010
- Employees
- 12
- HQ
- New York City, NY, US
Price Chart
- Market Cap
- $36.84K
- P/E
- -0.01
- P/S
- 0.39
- P/B
- -0.00
- EV/EBITDA
- -4.23
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -281.13%
- Net Margin
- -4995.23%
- ROE
- 21.36%
- ROIC
- 4.85%
- Revenue
- $95.33K · 0.00%
- Net Income
- $-4,762,000 · 53.30%
- EPS
- $-0.01 · 62.56%
- Op Income
- $-268,000
- FCF YoY
- 54.68%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -12.34
- Avg Volume
- 10.64K
Get TickerSpark's AI analysis on AMBS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 17 | Flanigan Conn | other | 0 |
| Feb 23, 17 | Flanigan Conn | other | 0 |
| Feb 1, 16 | COMMISSIONG GERALD | other | 45,283 |
| Apr 9, 15 | FARRELL ROBERT EDWARD | buy | 200,000 |
| Apr 8, 15 | COMMISSIONG GERALD | buy | 203,000 |
| Apr 8, 15 | COMMISSIONG GERALD | buy | 37,000 |
| Jan 12, 15 | Huffman Donald D | other | 6,490,000 |
| Nov 19, 14 | FARRELL ROBERT EDWARD | buy | 133,333 |
| Nov 20, 14 | COMMISSIONG GERALD | buy | 10,000 |
| Nov 20, 14 | COMMISSIONG GERALD | buy | 36,000 |
Our AMBS coverage
Recent articles, reports, and earnings notes.
No research on AMBS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMBS report →Similar companies
Peers in the same neighborhood.